Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week Phase 3 studies in patients with moderate to severe plaque psoriasis

被引：0
|
作者：
Kaur, M. [1 ]
Merola, J. [2 ]
Tatulych, S. [3 ]
Mamolo, C. [3 ]
Lan, S. [3 ]
机构：
[1] Pfizer, Collegeville, PA USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Dermatol, Boston, MA USA
[3] Pfizer, Groton, CT USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷
关键词：
psoriasis; nails; tofacitinib;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P157
引用
收藏
页码：81 / 81
页数：1
相关论文
共 50 条
  • [31] Early clinical response as a predictor of subsequent response to tofacitinib treatment: Results from two phase 3 studies of subjects with moderate to severe plaque psoriasis
    Tan, Huaming
    Valdez, Hernan
    Wolk, Robert
    Tallman, Anna
    Gordon, Kenneth B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB244 - AB244
  • [32] Tofacitinib for the treatment of moderate-to-severe psoriasis
    Chiricozzi, Andrea
    Faleri, Sara
    Saraceno, Rosita
    Bianchi, Luca
    Buonomo, Oreste
    Chimenti, Sergio
    Chimenti, Maria Sole
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (04) : 443 - 455
  • [33] Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
    Reich, Kristian
    Papp, Kim A.
    Blauvelt, Andrew
    Langley, Richard G.
    Armstrong, April
    Warren, Richard B.
    Gordon, Kenneth B.
    Merola, Joseph F.
    Okubo, Yukari
    Madden, Cynthia
    Wang, Maggie
    Cioffi, Christopher
    Vanvoorden, Veerle
    Lebwohl, Mark
    LANCET, 2021, 397 (10273): : 487 - 498
  • [34] Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis
    Ma, Guangli
    Xie, Rujia
    Strober, Bruce
    Langley, Richard
    Ito, Kaori
    Krishnaswami, Sriram
    Wolk, Robert
    Valdez, Hernan
    Rottinghaus, Scott
    Tallman, Anna
    Gupta, Pankaj
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (06): : 587 - 596
  • [35] The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
    Reich, K.
    Gooderham, M.
    Green, L.
    Bewley, A.
    Zhang, Z.
    Khanskaya, I.
    Day, R. M.
    Goncalves, J.
    Shah, K.
    Piguet, V.
    Soung, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 507 - 517
  • [36] Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
    Dauden, Esteban
    de la Cueva, Pablo
    Salgado-Boquete, Laura
    Llamas-Velasco, Mar
    Fonseca, Eduardo
    Pau-Charles, Ignasi
    Asensio, David
    Guila, Meritxell
    Manuel Carrascosa, Jose
    DERMATOLOGY AND THERAPY, 2023, 13 (01) : 329 - 345
  • [37] Improvements in scalp and nail psoriasis with apremilast treatment in patients with moderate to severe plaque psoriasis with and without a history of psoriatic arthritis
    Crowley, Jeffrey
    Gooderham, Melinda
    Richter, Sven
    Shi, Rebecca
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB62 - AB62
  • [38] Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
    Esteban Daudén
    Pablo de la Cueva
    Laura Salgado-Boquete
    Mar Llamas-Velasco
    Eduardo Fonseca
    Ignasi Pau-Charles
    David Asensio
    Meritxell Guilà
    José Manuel Carrascosa
    Dermatology and Therapy, 2023, 13 : 329 - 345
  • [39] Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective study
    Valenti, Mario
    Gargiulo, Luigi
    Ibba, Luciano
    Cortese, Andrea
    Toso, Francesco
    Orsini, Diego
    Lora, Viviana
    Frascione, Pasquale
    Sena, Paolo
    Carugno, Andrea
    Assorgi, Chiara
    Costanzo, Antonio
    Narcisi, Alessandra
    JOURNAL OF DERMATOLOGY, 2024, 51 (06): : 839 - 843
  • [40] Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study
    Torres, Tiago
    Varela, Paulo
    Bastos, Pedro Mendes
    Magina, Sofia
    Henrique, Martinha
    Ferreira, Paulo
    DRUGS IN CONTEXT, 2024, 13
12345